RePORT ⟩ RePORTER

Project Details

Long-term consequences of SARS-CoV-2 infection and COVID-19 disease among American Indians: an ambidirectional cohort study in the Cherokee Nation

Parent Project Number5S06GM146122-02

Sub-Project ID9322

Contact PI/Project LeaderKUHN, KATRIN GAARDBO

Awardee OrganizationCHEROKEE NATION

Description

Abstract Text

ABSTRACT Following the immediate effect of acute COVID-19 on patients and healthcare systems, it has now also become apparent that as many as 35% of COVID patients experience long-term health consequences of their infection. These consequences are reported to include heart-related problems, digestive issues, fatigue and dizziness, as well as anxiety and depression, but the full spectrum of symptoms and their duration is still unknown. American Indian people have been disproportionately affected by the COVID pandemic due to underlying medical conditions combined with high COVID-19 incidence and mortality, and general health inequalities. As a result, the impact of long-term symptoms is also expected to be severe in this population. In this study, we propose to examine the extent of long-term symptoms following SARS-CoV-2 infection among American Indian people residing in the Cherokee Nation Reservation. Given the strong impact of COVID-19 and the lack of understanding of its long-term effect in the Cherokee Nation, there is a crucial need for improved management among these patients in the community. This study will be among the first to assess long-term symptoms in an American Indian population and as such will establish a precedent and framework for future studies in the American Indian population. The overall goal of the study is to identify and quantify long-term COVID symptoms among American Indian people and to develop guidelines for how to predict, assess and manage these symptoms. This is an ambidirectional cohort study following a total of 200 persons retrospectively (tested for infection within the past six months) and prospectively (tested for infection from the time the study is initiated, and onwards). Using this approach, we will achieve our aims of identifying long-term symptoms in SARS-CoV-2 positive versus negative American Indian persons, predicting who is at risk of developing these symptoms and ultimately produce guidelines for predicting and identifying who is most at risk of becoming affected by COVID symptoms in the long run and how manage the symptoms either in centralized dedicated healthcare clinics or through primary care providers.

Public Health Relevance Statement

Data not available.

NIH Spending Category

American Indian or Alaska NativeBiodefense and Related CountermeasuresBuilding Research Capacity at Institutions with Limited NIH FundingClinical ResearchCoronavirusesCoronaviruses Disparities and At-Risk PopulationsEmerging Infectious DiseasesGeneticsHealth Disparities ResearchHealth Disparities and Racial or Ethnic Minority Health ResearchHealth ServicesHuman GenomeInfectious DiseasesPost-Acute Sequelae of SARS-CoV-2 infection (PASC) including Long COVIDRacial and Ethnic Minority Health ResearchRural Health

Project Terms

5 year oldAcuteAddressAdultAffectAgeAmericanAmerican IndiansAnxietyCOVID-19COVID-19 impactCOVID-19 pandemicCOVID-19 patientCOVID-19 riskCOVID-19 testCardiovascular systemCaringCessation of lifeCherokee IndianChildChild HealthClinicCohort StudiesCoinCommunitiesCommunity SurveysContact TracingDedicationsDiseaseDizzinessEligibility DeterminationFatigueFutureGenderGoalsGuidelinesHealthHealth care facilityHealthcareHealthcare SystemsHeartHospitalizationIncidenceIndian reservationInfectionIntensive CareInterviewKnowledgeLong COVIDLong-Term EffectsMedicalMemoryMental DepressionNative American Research Center for HealthOklahomaOutpatientsPaperParticipantPatient riskPatientsPersonsPopulationPrevalencePublic HealthPublishingQuestionnairesRaceReportingReview LiteratureRiskSARS-CoV-2 infectionSARS-CoV-2 negativeSARS-CoV-2 positiveSeverity of illnessSurveysSymptomsTelephone InterviewsTest ResultTestingTime StudyVisitcohortcomorbiditycoronavirus diseaseexperiencegastrointestinalhealth inequalitieshigh riskimprovedlong term consequences of COVID-19long-term sequelaemembermortalitypandemic diseasepersistent symptompost SARS-CoV-2 infectionpost-COVID-19primary care providerprospectivepsychologicrural countiessevere COVID-19symptom managementtribal community

Details

Contact PI/ Project Leader

Name

KUHN, KATRIN GAARDBO

Title

Contact

Other PIs

Not Applicable

Program Official

Name

Contact

Email not available

Organization

Name

CHEROKEE NATION

City

TAHLEQUAH

Country

UNITED STATES (US)

Department Type

Unavailable

Organization Type

Other Domestic Non-Profits

State Code

Congressional District

Other Information

Opportunity Number

PAR-20-125

Study Section

Special Emphasis Panel[ZRG1-BDCN-N]

Fiscal Year

2023

Award Notice Date

23-August-2023

Administering Institutes or Centers

National Institute of General Medical Sciences

CFDA Code

DUNS Number

077345494

UEI

TBAHL1WANLF3

Project Start Date

20-September-2022

Project End Date

31-July-2026

Budget Start Date

01-August-2023

Budget End Date

31-July-2024

Project Funding Information for 2023

Total Funding

$345,236

Direct Costs

$330,112

Indirect Costs

$15,124

Year	Funding IC	FY Total Cost by IC
2023	National Institute of General Medical Sciences	$345,236

NIH Categorical SpendingClick here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES	$69,821	American Indian or Alaska Native; Biodefense and Related Countermeasures; Building Research Capacity at Institutions with Limited NIH Funding; Clinical Research; Coronaviruses; Coronaviruses Disparities and At-Risk Populations; Emerging Infectious Diseases; Health Disparities Research; Health Disparities and Racial or Ethnic Minority Health Research; Health Services; Infectious Diseases; Post-Acute Sequelae of SARS-CoV-2 infection (PASC) including Long COVID; Racial and Ethnic Minority Health Research; Rural Health
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES	$88,201	American Indian or Alaska Native; Biodefense and Related Countermeasures; Building Research Capacity at Institutions with Limited NIH Funding; Clinical Research; Coronaviruses; Coronaviruses Disparities and At-Risk Populations; Emerging Infectious Diseases; Health Disparities Research; Health Disparities and Racial or Ethnic Minority Health Research; Health Services; Infectious Diseases; Post-Acute Sequelae of SARS-CoV-2 infection (PASC) including Long COVID; Racial and Ethnic Minority Health Research; Rural Health
NATIONAL HUMAN GENOME RESEARCH INSTITUTE	$30,727	American Indian or Alaska Native; Biodefense and Related Countermeasures; Building Research Capacity at Institutions with Limited NIH Funding; Clinical Research; Coronaviruses; Coronaviruses Disparities and At-Risk Populations; Emerging Infectious Diseases; Genetics; Health Disparities Research; Health Disparities and Racial or Ethnic Minority Health Research; Health Services; Human Genome; Infectious Diseases; Post-Acute Sequelae of SARS-CoV-2 infection (PASC) including Long COVID; Racial and Ethnic Minority Health Research; Rural Health
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	$125,760	American Indian or Alaska Native; Biodefense and Related Countermeasures; Building Research Capacity at Institutions with Limited NIH Funding; Clinical Research; Coronaviruses; Coronaviruses Disparities and At-Risk Populations; Emerging Infectious Diseases; Health Disparities Research; Health Disparities and Racial or Ethnic Minority Health Research; Health Services; Infectious Diseases; Post-Acute Sequelae of SARS-CoV-2 infection (PASC) including Long COVID; Racial and Ethnic Minority Health Research; Rural Health
OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH	$30,728	American Indian or Alaska Native; Biodefense and Related Countermeasures; Building Research Capacity at Institutions with Limited NIH Funding; Clinical Research; Coronaviruses; Coronaviruses Disparities and At-Risk Populations; Emerging Infectious Diseases; Health Disparities Research; Health Disparities and Racial or Ethnic Minority Health Research; Health Services; Infectious Diseases; Post-Acute Sequelae of SARS-CoV-2 infection (PASC) including Long COVID; Racial and Ethnic Minority Health Research; Rural Health

Sub Projects

No Sub Projects information available for 5S06GM146122-02 9322

Publications

Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.

No Publications available for 5S06GM146122-02 9322

Patents

No Patents information available for 5S06GM146122-02 9322

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 5S06GM146122-02 9322

Clinical Studies

No Clinical Studies information available for 5S06GM146122-02 9322

News and More

Section Menu